{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:47:48Z","timestamp":1783784868708,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Hypophosphatasia (HPP) is a rare, inherited metabolic disorder due to a deficiency of tissue-nonspecific alkaline phosphatase, characterized by defective bone and teeth mineralization with consequent problems, including respiratory failure in severe types of HPP. Severe patients exhibit other disease-related manifestations, including neurological manifestations, which make HPP complex and difficult to manage. Enzyme replacement therapy with asfotase alfa is a disease-specific treatment for skeletal manifestations in pediatric patients. We present a patient with perinatal HPP who had a severe clinical course with respiratory insufficiency during infancy requiring a higher dose of asfotase alfa than recommended (12 mg\/kg\/week). After improvement of respiratory function and outgrowing the higher dose, the patient was maintained on the standard dose (6 mg\/kg\/week) from the age of 3 years. At 6 years of age, unexplained clinical and radiographic deterioration occurred while laboratory parameters remained normal. Following a traumatic humerus fracture that occurred after several months, asfotase alfa was increased to 10 mg\/kg\/week. Remarkable clinical improvement was observed and the patient regained the ability to walk unassisted 3 months after the dose correction. The rickets severity score changed from 10 to 3.5 within 14 months. No side effects from the higher drug dose have been noticed. The remaining challenge in this patient was a neurodevelopmental disorder. In conclusion, the standard dose of asfotase alfa was not sufficient to treat the skeletal manifestations of HPP in our patient, indicating that some perinatal HPP patients should be treated with higher doses to reach treatment goals. Although bone disease and patient outcomes have been improved with tailored drug doses, neurological manifestations of HPP remain challenging.<\/jats:p>","DOI":"10.3389\/fendo.2025.1587807","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:16:44Z","timestamp":1750220204000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Suboptimal response to standard-dose asfotase alfa in perinatal hypophosphatasia indicates a need for individualized dosing"],"prefix":"10.3389","volume":"16","author":[{"given":"Danijela","family":"Petkovi\u0107 Ramad\u017ea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"\u017digman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mislav","family":"\u010cavka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Bari\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.14","article-title":"Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment","volume":"12","author":"Whyte","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B2","unstructured":""},{"key":"B3","doi-asserted-by":"publisher","first-page":"e63781","DOI":"10.1002\/ajmg.a.63781","article-title":"New insights into the landscape of ALPL gene variants in patients with hypophosphatasia from the Global HPP Registry","volume":"17","author":"Kishnani","year":"2024","journal-title":"Am J Med Genet A"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235676","article-title":"Hypophosphatasia","volume":"10","author":"Tournis","year":"2021","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-016-0309-0","article-title":"Hypophosphatasia","volume":"14","author":"Linglart","year":"2016","journal-title":"Curr Osteoporos Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00247-018-4239-0","article-title":"Differential diagnosis of perinatal hypophosphatasia: radiologic perspectives","volume":"49","author":"Offiah","year":"2019","journal-title":"Pediatr Radiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06844-1","article-title":"Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults","volume":"35","author":"Khan","year":"2024","journal-title":"Osteoporos Int"},{"key":"B8","unstructured":""},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3462","article-title":"Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia","volume":"101","author":"Whyte","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02335","article-title":"Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: A phase 2 open-label study","volume":"104","author":"Hofmann","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","article-title":"Asfotase alfa for infants and young children with hypophosphatasia: 7-year outcomes of a single-arm, open-label, phase 2 extension trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","unstructured":""},{"key":"B13","article-title":"Hypophosphatasia: phenotypic variability and possible Croatian origin of the c.1402G>A mutation of TNSALP gene","volume":"33","author":"Petkovi\u0107 Ramadza","year":"2009","journal-title":"Coll Antropol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"A261","DOI":"10.1210\/jendso\/bvab048.530","article-title":"Frequency of ectopic calcifications among patients with hypophosphatasia in the global HPP registry","volume":"5","author":"Linglart","year":"2021","journal-title":"J Endocr Soc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2017.07.010","article-title":"Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa","author":"Kishnani","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e25426","DOI":"10.7759\/cureus.25426","article-title":"Multidisciplinary management of infantile hypophosphatasia resulting in radiographic and clinical improvement: a case report","volume":"14","author":"Qubain","year":"2022","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.590455","article-title":"Case Report: Efficacy of reduced doses of asfotase alfa replacement therapy in an infant with hypophosphatasia who lacked severe clinical symptoms","volume":"11","author":"Fujisawa","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.01.020","article-title":"Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene","volume":"40","author":"Baumgartner-Sigl","year":"2007","journal-title":"Bone"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123338","article-title":"Tissue-nonspecific alkaline phosphatase, a possible mediator of cell maturation: towards a new paradigm","volume":"10","author":"Sato","year":"2021","journal-title":"Cells"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2013.02.017","article-title":"Compound heterozygosity of two functional null mutations in the ALPL gene associated with deleterious neurological outcome in an infant with hypophosphatasia","volume":"55","author":"Hofmann","year":"2013","journal-title":"Bone"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000520341","article-title":"Lethal encephalopathy in an infant with hypophosphatasia despite enzyme replacement therapy","volume":"94","author":"Raimann","year":"2021","journal-title":"Horm Res Paediatr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4691-6","article-title":"Neurological symptoms in hypophosphatasia","volume":"30","author":"Colazo","year":"2019","journal-title":"Osteoporos Int"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1587807\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:16:45Z","timestamp":1750220205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1587807\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":22,"alternative-id":["10.3389\/fendo.2025.1587807"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1587807","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1587807"}}